Physician profile
Nandini Razdan
NPI 1790313153
$3,860.72
in general payments reported to CMS, 2019-2025
17 companies · $2,829 in 2025
The $2,829 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $69.85 · 2021: $43.27 · 2022: $201 · 2023: $95.13 · 2024: $623 · 2025: $2,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445 · Travel and Lodging: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,444.72 |
| Travel and Lodging | $1,102.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,830.26 | 2024-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $611.24 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $553.93 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $265.27 | 2023-2025 | Farxiga, Brilinta, Lokelma |
| Boston Scientific Corporation | $115.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $85.53 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.03 | 2022 | |
| Abiomed | $64.02 | 2025 | |
| Abbvie INC. | $50.01 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $45.62 | 2024 | Xarelto |
| Intercept Pharmaceuticals, INC. | $35.72 | 2020 | |
| Mannkind Corporation | $27.97 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $26.62 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $22.26 | 2025 | |
| Amgen INC. | $15.23 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $14.24 | 2024 | Inspire |
| Fidia Pharma USA INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nandini Razdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.